Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: Anticancer Drugs. 2020 Sep;31(8):759–775. doi: 10.1097/CAD.0000000000000962

Figure 6. GSK346294A suppresses mammosphere formation and stem-cell like properties of TNBC cells.

Figure 6.

(A) Peripheral blood harvested from the TU-BcX-4IC in vivo treatment experiment (DMSO vehicle, GSK346294A treatments) was analyzed using flow cytometry for the presence of tumor circulating stem cells characterized as HLA+CD44+CD24-. n = 4 mice/treatment group. (B) Patient-derived organoids from the TU-BcX-4IC model were treated with GSK346294A (1μM) or DMSO control for 72 hours before staining with a Live/Dead kit (PromoKine). Calcein-AM (green) highlights viable cells and EthD-III (red) highlights dead cells when imaged with immunofluorescence. (C) TU-BcX-4IC and (D) MDA-MB-231 M2 mammospheres were treated with the PKIS compounds (GSK346294A, GSK448459A) as well as potent PLK inhibitors (BI2536, BI6727). After 7 days of treatment, the mammospheres were imaged and areas were quantified. (E) Representative images of TU-BcX-4IC and MDA-MB-231 mammospheres treated with PKIS compounds and selective PLK inhibitors.